Cargando…

Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study

Background and Objectives: In October 2018, the International Federation of Gynecology and Obstetrics (FIGO) revised its classification of advanced stages of cervical cancer. The main points of the classification are as follows: stage IIIC is newly established; pelvic lymph node metastasis is stage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kagabu, Masahiro, Nagasawa, Takayuki, Tatsuki, Shunsuke, Fukagawa, Yasuko, Tomabechi, Hidetoshi, Takatori, Eriko, Kaido, Yoshitaka, Shoji, Tadahiro, Baba, Tsukasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227555/ https://www.ncbi.nlm.nih.gov/pubmed/34072478 http://dx.doi.org/10.3390/medicina57060548

Ejemplares similares

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease
por: Shoji, Tadahiro, et al.
Publicado: (2019)

Immunotherapy for Uterine Cervical Cancer
por: Kagabu, Masahiro, et al.
Publicado: (2019)

Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
por: Kagabu, Masahiro, et al.
Publicado: (2020)

A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)
por: Nagasawa, Takayuki, et al.
Publicado: (2023)

A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass
por: Takatori, Eriko, et al.
Publicado: (2016)

A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review
por: Shoji, Tadahiro, et al.
Publicado: (2016)

Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
por: Chang, Hong, et al.
Publicado: (2023)

Treatment of FIGO 2018 stage IIIC cervical cancer with different local tumor factors
por: Ye, Yanna, et al.
Publicado: (2023)

A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report
por: Takatori, Eriko, et al.
Publicado: (2015)

Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review
por: Qin, Fengying, et al.
Publicado: (2022)

Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients With Stage IIIC Cervical Cancer
por: Long, Xingtao, et al.
Publicado: (2023)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System
por: Liu, Xiaoliang, et al.
Publicado: (2020)

Discussion on the rationality of FIGO 2018 stage IIIC for cervical cancer with oncological outcomes: a cohort study
por: Li, Zhiqiang, et al.
Publicado: (2022)

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass
por: Shoji, Tadahiro, et al.
Publicado: (2016)

Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports
por: Shoji, Tadahiro, et al.
Publicado: (2018)

Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer
por: Aigner, Karl R., et al.
Publicado: (2021)

Image-guided intensity-modulated radiotherapy in patients with FIGO IIIC1 cervical cancer: efficacy, toxicity and prognosis
por: Meng, Qingyu, et al.
Publicado: (2023)

Rationality of FIGO 2018 IIIC restaging of cervical cancer according to local tumor size: A cohort study
por: Duan, Hui, et al.
Publicado: (2023)

Nomograms Predicting Survival of Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy Based on the 2018 FIGO Staging System
por: Meng, Qingyu, et al.
Publicado: (2022)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
por: Kuhn, W, et al.
Publicado: (1999)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Pretreatment [(18)F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1
por: Burchardt, Ewa, et al.
Publicado: (2021)

Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study
por: Ye, Yanna, et al.
Publicado: (2023)

Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2–IVA cervical cancer and its clinical prognostic factors
por: Fujiwara, Masateru, et al.
Publicado: (2015)

A comprehensive analysis of the factors of positive pelvic lymph nodes on survival of cervical cancer patients with 2018 FIGO stage IIIC1p
por: Yan, Ding-Ding, et al.
Publicado: (2019)

A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
por: Shoji, Tadahiro, et al.
Publicado: (2014)

The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy
por: Topkan, Erkan, et al.
Publicado: (2023)

D2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy
por: Peng, Jin, et al.
Publicado: (2016)

Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX
por: Takatori, Eriko, et al.
Publicado: (2013)

Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer
por: Kuroda, Yuuki, et al.
Publicado: (2012)

Comparison of concurrent chemoradiotherapy followed by radical surgery and high-dose-rate intracavitary brachytherapy: a retrospective study of 240 patients with FIGO stage IIB cervical carcinoma
por: Wang, Ning, et al.
Publicado: (2014)

Invasive Paget's disease of the vulva treated with a combination of surgery and concurrent chemoradiotherapy: A case report
por: Inayama, Yoshihide, et al.
Publicado: (2018)

Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents
por: Takatori, Eriko, et al.
Publicado: (2012)

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
por: Takatori, Eriko, et al.
Publicado: (2014)

Chemoradiotherapy and concurrent radiofrequency thermal therapy to treat primary rectal cancer and prediction of treatment responses
por: Shoji, Hisanori, et al.
Publicado: (2017)

Outcomes of “sandwich” chemoradiotherapy compared with chemotherapy alone for the adjuvant treatment of FIGO stage III endometrial cancer
por: Wang, Shao-Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4hoaafgetohgro44it2qlu9s7v